{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:15:52Z","timestamp":1740179752369,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-020-00309-z","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T10:03:35Z","timestamp":1597831415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Agile analytics to support rapid knowledge pipelines"],"prefix":"10.1038","volume":"3","author":[{"given":"Wade L.","family":"Schulz","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-2291","authenticated-orcid":false,"given":"Joseph C.","family":"Kvedar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"309_CR1","doi-asserted-by":"publisher","unstructured":"Haimovich, A. et al Development and validation of the COVID-19 severity index (CSI): a prognostic tool for early respiratory decompensation. medRxiv, https:\/\/doi.org\/10.1101\/2020.05.07.20094573 (2020).","DOI":"10.1101\/2020.05.07.20094573"},{"key":"309_CR2","doi-asserted-by":"publisher","unstructured":"Morales, D. R. et al. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study. medRxiv, https:\/\/doi.org\/10.1101\/2020.06.11.20125849 (2020).","DOI":"10.1101\/2020.06.11.20125849"},{"key":"309_CR3","doi-asserted-by":"publisher","unstructured":"International Consortium for Clinical Characterization of patients with SARS-CoV-2 by EHR (4CE) Consortium. npj Digital Med. https:\/\/doi.org\/10.1038\/s41746-020-00308-0 (2020).","DOI":"10.1038\/s41746-020-00308-0"},{"key":"309_CR4","doi-asserted-by":"publisher","unstructured":"Mehra, M. R., Desai, S. S., Kuy, S. R., Henry, T. D. & Patel, A. N. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2021225 (2020).","DOI":"10.1056\/NEJMc2021225"},{"key":"309_CR5","doi-asserted-by":"crossref","unstructured":"Mehra, M. R., Desai, S. S., Ruschitzka, F. & Patel, A. N. Retracted: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673620311806?via%3Dihub (2020).","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"309_CR6","unstructured":"i2b2\u2014Informatics for Integrating Biology & the Bedside. https:\/\/www.i2b2.org\/."},{"key":"309_CR7","unstructured":"OHDSI\u2014Observational Health Data Sciences and Informatics. https:\/\/ohdsi.org\/."},{"key":"309_CR8","unstructured":"National Center for Advancing Translational Sciences. National COVID Cohort Collaborative (N3C). https:\/\/ncats.nih.gov\/n3c."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00309-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:27:22Z","timestamp":1670380042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-020-00309-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["309"],"URL":"https:\/\/doi.org\/10.1038\/s41746-020-00309-z","relation":{},"ISSN":["2398-6352"],"issn-type":[{"type":"electronic","value":"2398-6352"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.L.S. was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to HugoHealth, a personal health information platform, and co-founder of Refactor Health, an AI-augmented data management platform for healthcare; and is a consultant for Interpace Diagnostics Group, a molecular diagnostics company. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the Food and Drug Administration to develop methods for postmarket surveillance of medical devices; was a recipient of a research grant from Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin\/Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant\/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. J.C.K. is an advisor to and shareholder in LuminDx, and FDNA. He is an advisor to Flare Capital, Puretech, ResApp Health, GoodRx and NuRx. He is a shareholder in and on the board of directors of Mobile Help. He is a shareholder in b.well and MD Revolution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}